專家和商界領(lǐng)袖認(rèn)為，由于人口老齡化和政策支持，加上公眾意識的不斷提高，中國早癌篩查市場將繼續(xù)擴(kuò)大，預(yù)計國內(nèi)企業(yè)將進(jìn)一步加強(qiáng)其創(chuàng)新和商業(yè)化能力。

If you ask anyone how to reduce the mortality rate of cancer patients, the answer may vary from person to person. Yet early detection and intervention probably will occur in most people's answers to that question.
如何降低癌癥患者的死亡率，對此人們的回答可能有所不同。然而，大多數(shù)人的答案可能都包括早期發(fā)現(xiàn)和干預(yù)。

New financing events for domestic early cancer screening startups have hit news headlines since the start of the year, despite slides in share prices of many listed biotech companies at home and abroad.
盡管國內(nèi)外許多生物技術(shù)上市公司股價下跌，但自今年年初以來，針對國內(nèi)早癌篩查初創(chuàng)公司的新融資活動占據(jù)了新聞頭條。

Thanks to population aging and policy support, together with growing public awareness, the early cancer screening market in China will continue to expand, and domestic enterprises are expected to further strengthen their innovation and commercialization capabilities, experts and business leaders said.
專家和商界領(lǐng)袖表示，由于人口老齡化和政策支持，加上公眾意識的不斷提高，中國早癌篩查市場將繼續(xù)擴(kuò)大，預(yù)計國內(nèi)企業(yè)將進(jìn)一步加強(qiáng)其創(chuàng)新和商業(yè)化能力。

Shi Lichen, founder of medical consulting firm Beijing Dingchen Consultancy, said cancer is a top killer in China, and boundless opportunities have been presented for early cancer detection industry players because they also target healthy people rather than just cancer patients.
醫(yī)療咨詢公司北京鼎臣咨詢創(chuàng)始人史立臣表示，在中國，癌癥是頭號殺手，早癌篩查行業(yè)的從業(yè)者有著無限機(jī)會，因?yàn)樗麄兠闇?zhǔn)的不僅僅是癌癥患者，還有健康人群。

"Chinese authorities have reiterated on various occasions the importance of early detection and intervention for the prevention and control of cancer. The market prospects are very promising," he said.
史立臣稱：“中國官方多次強(qiáng)調(diào)早期發(fā)現(xiàn)和干預(yù)對預(yù)防和控制癌癥的重要性。早癌篩查市場前景十分光明。”

In a new plan to spur the bioeconomy during the 14th Five-Year Plan period (2021-25), the National Development and Reform Commission said it is necessary to promote deep integration of advanced technologies such as genetic testing and disease prevention, and to carry out early screening programs for major diseases, including tumors.
國家發(fā)展改革委對外發(fā)布的《“十四五”生物經(jīng)濟(jì)發(fā)展規(guī)劃》提出，要推動基因檢測等先進(jìn)技術(shù)與疾病預(yù)防深度融合，開展腫瘤等重大疾病早期篩查。

A report by early detection information provider Zao Dx said 26 financing events were announced last year in China's early cancer detection industry, among which 15 came at more than 100 million yuan ($14.92 million) each. The combined value of financing reached more than 6.6 billion yuan last year.
早篩網(wǎng)的一份報告稱，2021年中國早癌篩查行業(yè)宣布了26項(xiàng)融資活動，其中15項(xiàng)融資活動的金額均超過1億元人民幣，2021年融資總額超過66億元。

Zhou Jun, CEO of Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, said a root cause for investors' sustained enthusiasm for early cancer screening is that although various innovative therapies have been made available in the market in recent years for cancer, once the disease progresses to the middle and late stages, the benefits from drugs will become very limited, while related expenditures at both the individual level and the society level can be huge.
貝瑞基因首席執(zhí)行官周珺表示，投資者對早癌篩查行業(yè)投資熱情持續(xù)高漲的一個根本原因是，盡管近年來市場上有各種創(chuàng)新療法治療癌癥，但一旦癌癥發(fā)展到中晚期，藥物的作用將變得非常有限，而個人和社會層面的相關(guān)支出可能會非常巨大。

In particular, the application of liquid biopsy technology based on high-throughput sequencing has greatly increased the probability of the detection and early intervention of cancer, he said.
周珺稱，基于高通量測序的液體活檢技術(shù)的應(yīng)用大大提高了癌癥檢測和早期干預(yù)的可能性。

"With the commercial application of next-generation sequencing, we can enable alerts for tumors at a very early stage," he said.
他說：“隨著下一代測序技術(shù)的商業(yè)應(yīng)用，我們可以在腫瘤早期發(fā)出警報。”

However, analysts said large-scale rollouts of early cancer screening in China require improvements in not only cancer screening technology and policy support, but also in payments, clinical applications and regulations to spur the commercialization of related products.
然而，分析人士表示，中國大規(guī)模開展早癌篩查不僅需要改進(jìn)癌癥篩查技術(shù)和政策支持，還需要完善支付、臨床應(yīng)用和監(jiān)管，以推動相關(guān)產(chǎn)品的商業(yè)化。

"As domestic players started almost at the same time as their foreign counterparts, their overall competence in developing new solutions is somehow of the same level as foreign enterprises," said Shi of Beijing Dingchen Consultancy.
史立臣表示：“由于國內(nèi)企業(yè)幾乎與國外同行同時起步，他們在開發(fā)新解決方案方面的總體能力在某種程度上與外國企業(yè)相當(dāng)。”

"Yet the differences will present themselves among the capabilities to commercialize products," Shi said, adding major obstacles Chinese enterprises face for successful commercialization mainly include not only how to improve product efficacy and reduce pricing, but also how to get included in public or commercial medical insurance programs.
“然而，差異表現(xiàn)在產(chǎn)品商業(yè)化的能力上，中國企業(yè)成功商業(yè)化面臨的主要障礙不僅包括如何提高產(chǎn)品功效和降低價格，還包括如何加入公共或商業(yè)醫(yī)療保險計劃。”

According to a report by Haitong International Securities Group Ltd, China's early cancer detection market will reach more than 162 billion yuan in value within 10 years.
根據(jù)海通國際證券集團(tuán)有限公司的一份報告，中國早癌篩查市場估值將在10年內(nèi)超過1620億元人民幣。

A report by VCBeat Research said about 70 percent of Chinese cancer patients are already at the middle-to-late stage of the disease when they seek medical advice for the first time.
動脈網(wǎng)的一份報告顯示，約70%的中國癌癥患者在首次就診時已經(jīng)處于疾病的中晚期。

Zhou, with Berry Oncology, said both central and local Chinese authorities have released guidelines and policies to create better development conditions for the industry. However, more detailed rules for better implementation of those guidelines and policies are expected to help enterprises realize the commercialization of their research and innovations.
周珺稱，中央和地方政府都發(fā)布了指導(dǎo)方針和政策，為早癌篩查行業(yè)創(chuàng)造更好的發(fā)展條件。更好地細(xì)化落實(shí)這些指導(dǎo)方針和政策可以幫助企業(yè)實(shí)現(xiàn)其研究和創(chuàng)新的商業(yè)化。

來源：中國日報
編譯：董靜